Satellos research published in Nature Comms

Executive Summary

• Satellos Bioscience announced the publication of new research in Nature Communications validating its novel therapeutic approach for Duchenne muscular dystrophy (DMD).
• The study, conducted by the Ottawa Hospital Research Institute (OHRI), identifies DMD as a stem cell disease characterized by intrinsic muscle stem cell dysfunction occurring during fetal development, prior to inflammation or tissue degeneration.
• The research demonstrates that blocking the protein AAK1 can restore muscle stem cell polarity and regeneration, supporting the clinical potential of Satellos' lead candidate, SAT-3247.

Key Details

• Publication: The findings were published in Nature Communications under the title "Intrinsic dysfunction in muscle stem cells lacking dystrophin begins during secondary myogenesis."
• Research Team: Authored by OHRI researchers, including Dr. Michael Rudnicki (Satellos co-founder and chief discovery officer).
• Key Scientific Findings:
  • DMD begins as a stem cell disease where muscle stem cells lose polarity and produce fewer myogenic progenitors, leading to fewer and smaller muscle fibers.
  • These intrinsic changes arise during fetal muscle development before the onset of inflammation or tissue degeneration.
  • Muscle stem cells lacking dystrophin can be induced to achieve polarity, generate new progenitor cells, and form normal amounts of muscle by blocking the activity of the protein AAK1.
• Therapeutic Approach: Unlike existing treatments that aim to help patients produce dystrophin, Satellos' approach focuses on restoring muscle regeneration through the targeted inhibition of AAK1.
• Lead Candidate: SAT-3247 is a proprietary, oral, small molecule drug designed to regenerate skeletal muscle lost in DMD and other degenerative conditions. It is being developed independent of dystrophin and exon mutation status.
• Company Strategy: Satellos is leveraging its proprietary discovery platform, MyoReGenX, to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may offer therapeutic benefits.

Notable Quotes

• "These findings make it abundantly clear that Duchenne begins as a failure of muscle stem cells to build and maintain muscle -- without any evidence of myofiber fragility or damage. By modulating AAK1, we have demonstrated a powerful means to regulate polarity, normalize stem cell function and enhance muscle formation in dystrophic models, pointing to a compelling path toward regenerative treatment strategies." — Dr. Michael Rudnicki, Senior Author
• "These findings further validate our conviction that correcting stem-cell dysfunction is essential to changing the trajectory of Duchenne. We congratulate Dr. Rudnicki and his OHRI colleagues for uncovering and confirming muscle biology that may open doors to more effective intervention." — Frank Gleeson, Co-founder and CEO